Salt-Wasting Syndromes
Salt-wasting syndromes encompass a spectrum of inherited and acquired disorders characterized by renal sodium loss, hyponatremia, and volume depletion, with Bartter syndrome representing the most well-characterized inherited form requiring immediate sodium chloride supplementation (5-10 mmol/kg/day) plus NSAIDs, while cerebral salt wasting demands aggressive isotonic saline replacement to prevent life-threatening hypovolemia.
Causes
Inherited Salt-Wasting Tubulopathies
Bartter Syndrome is the prototypical genetic salt-wasting disorder, with five distinct subtypes (BS1-5) caused by mutations affecting salt reabsorption in the thick ascending limb of Henle's loop 1:
- Type 1 (SLC12A1): NKCC2 transporter defect, autosomal recessive
- Type 2 (KCNJ1): ROMK potassium channel defect, autosomal recessive
- Type 3 (CLCNKB): ClC-Kb chloride channel defect, autosomal recessive (milder phenotype)
- Type 4a/4b (BSND, CLCNKA+CLCNKB): Barttin or combined chloride channel defects, autosomal recessive, often with sensorineural deafness
- Type 5 (MAGED2): MAGE-D2 regulatory protein defect, X-linked recessive (transient)
Gitelman Syndrome affects the distal convoluted tubule and can be clinically indistinguishable from BS3 1.
Endocrine Salt-Wasting Syndromes
Beyond 21-hydroxylase deficiency (congenital adrenal hyperplasia), other endocrine causes include 2:
- Aldosterone synthase deficiency: Later presentation, less severe biochemistry
- Pseudohypoaldosteronism type 1: Renal (milder) vs. systemic (severe, earliest presentation with highest sodium requirements)
- Congenital adrenal hypoplasia: Rare, severe presentation
Acquired Cerebral Salt Wasting (CSW)
CSW occurs in critically ill patients with central nervous system pathology 3, 4:
- Neurosurgical conditions (subarachnoid hemorrhage, traumatic brain injury, subdural hematoma)
- Meningitis (including tuberculosis)
- Status epilepticus
- Brain tumors (medulloblastoma)
- Sepsis
- Ketamine infusion
Clinical Presentation
Bartter Syndrome
Antenatal/Neonatal Features (BS1, BS2, BS4) 1:
- Polyhydramnios with premature delivery
- Severe polyuria and dehydration at birth
- Failure to thrive
- Growth retardation
- Hypercalciuria with nephrocalcinosis (except BS3)
- Sensorineural deafness (BS4a/4b only)
Later Childhood Features (BS3, milder variants):
- Salt craving
- Muscle weakness
- Incidental hypokalemia
- Preserved urine concentrating ability
Cerebral Salt Wasting
- Hyponatremia (often severe, <130 mmol/L)
- Hypovolemia (critical distinguishing feature from SIADH)
- Increased urine output (polyuria, often >4 L/day)
Additional features include headache, altered mental status, seizures, and in LVAD patients, low-flow alarms due to preload dependence 6.
Endocrine Salt-Wasting Syndromes
Systemic pseudohypoaldosteronism type 1 presents earliest with the most severe biochemical derangements and highest sodium supplementation requirements at onset, while aldosterone synthase deficiency and renal pseudohypoaldosteronism type 1 present later with overlapping, less severe profiles 2.
Diagnostic Work-Up
Bartter Syndrome
Biochemical Hallmarks 1:
- Hypokalemia
- Hypochloremic metabolic alkalosis
- Normotensive hyperreninemic hyperaldosteronism
- Elevated urinary sodium and chloride (inappropriate for volume status)
- Hypercalciuria (BS1, BS2, BS4) vs. normal/low calciuria (BS3)
- Hypomagnesemia (variable)
Imaging:
- Renal ultrasound: Medullary nephrocalcinosis (BS1, BS2, BS4)
Genetic Testing: A diagnostic gene panel should include at minimum: SLC12A1, KCNJ1, CLCNKB, BSND, CLCNKA, MAGED2, plus SLC12A3 (Gitelman syndrome) for differential diagnosis 1. Additional genes may be included for broader differential (pseudohypoaldosteronism, Liddle syndrome, apparent mineralocorticoid excess).
Cerebral Salt Wasting vs. SIADH
Critical Distinction - Volume status is the key differentiator 5, 7:
CSW (Hypovolemic):
- Low jugular venous pressure
- Orthostatic hypotension
- Tachycardia
- Poor skin turgor
- Elevated BUN/creatinine ratio
- Elevated hematocrit
SIADH (Euvolemic/Hypervolemic):
- Normal jugular venous pressure
- No orthostatic changes
- Normal BUN/creatinine ratio
Overlapping Laboratory Features (cannot distinguish) 3, 5:
- Hyponatremia
- Hypouricemia with high fractional excretion of uric acid
- Urine osmolality > plasma osmolality
- Urine sodium often >30 mmol/L
- Normal renal, adrenal, thyroid function
Supportive Tests:
- Brain natriuretic peptide (BNP): May be elevated in CSW
- Uric acid: Typically low in both conditions
Endocrine Salt-Wasting Syndromes
Initial Evaluation 2:
- Serum sodium, potassium, chloride, bicarbonate
- Plasma renin activity and aldosterone
- Cortisol (rule out adrenal insufficiency)
- Urine sodium and osmolality
- Genetic testing for definitive diagnosis
Common Pitfall: Systemic pseudohypoaldosteronism type 1 may initially mimic BS2 in the neonatal period, requiring careful clinical and genetic differentiation 1.
Management
Bartter Syndrome
Sodium Chloride Supplementation 1:
- Dose: 5-10 mmol/kg/day (pharmacologic doses)
- Spread throughout the day for better tolerance
- Beyond infancy, spontaneous salt craving may provide partial supplementation
- Exception: Do NOT supplement in patients with secondary nephrogenic diabetes insipidus (hypernatremic dehydration with urine osmolality < plasma osmolality)
Potassium Chloride Supplementation 1:
- Use potassium chloride specifically (NOT potassium citrate, which worsens alkalosis)
- Do NOT aim for complete normalization of potassium (risk of complications)
- Severe hypokalemia can cause paralysis, rhabdomyolysis, cardiac arrhythmias
NSAIDs 1:
- Mainstay of treatment, especially in early childhood
- Inhibit prostaglandin E2 production (pathophysiologically driven by tubuloglomerular feedback)
- Exception: Avoid in transient BS5
- Long-term NSAID use carries theoretical risk of chronic kidney disease (data lacking)
Magnesium Supplementation 1:
- Use organic magnesium salts (better bioavailability)
- As needed for hypomagnesemia
Alternative Therapies (limited evidence):
- Potassium-sparing diuretics (amiloride, spironolactone)
- ACE inhibitors or angiotensin receptor blockers
- Evidence for efficacy, tolerability, and safety is limited 1
Prenatal Management (if polyhydramnios diagnosed) 1:
- Maternal NSAIDs carry significant fetal risks (ductus arteriosus constriction, necrotizing enterocolitis, intestinal perforation)
- Serial amniocentesis is an alternative
- Requires multidisciplinary team: maternal-fetal medicine, neonatology, pediatric cardiology, pediatric nephrology
- Fetal echocardiography mandatory if NSAIDs used
- Formal recommendation cannot be made due to lack of prospective data and publication bias
Cerebral Salt Wasting
Initial Treatment (European unifying protocol):
- 3% hypertonic saline boluses over 20 minutes via peripheral vein
- Goal: Increase serum sodium by 5 mEq/L over 1-2 hours
- This approach is safer when uncertain whether patient has CSW vs. SIADH
Ongoing Management:
- Isotonic saline infusion: 1:1 volume replacement for urine output
- Hypertonic saline boluses: Intermittent as needed
- Fludrocortisone: Daily mineralocorticoid supplementation
- Desmopressin: Low-dose to reduce polyuria
- Salt tablets: Maintain serum sodium 135-140 mmol/L
- Goal urine output: 2.5-3.5 L/day
Critical Consideration: In LVAD patients, CSW causes preload-dependent low-flow alarms requiring aggressive volume replacement 6. Failure to rapidly treat can lead to respiratory arrest, brainstem herniation, and death.
Treatment Duration: Mean time to correction of hyponatremia is approximately 20 days 4.
Endocrine Salt-Wasting Syndromes
General Principles 2:
- Sodium supplementation requirements vary by etiology (highest in systemic pseudohypoaldosteronism type 1)
- Mineralocorticoid therapy (fludrocortisone) for aldosterone deficiency states
- Time to electrolyte stabilization does not differ significantly across etiologies
- Growth outcomes are generally preserved with appropriate management
- Systemic pseudohypoaldosteronism type 1 shows greater auxological vulnerability
Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)
Newborn Screening 8:
- All newborns should be screened using two-tier protocol (initial immunoassay, confirmatory liquid chromatography/tandem mass spectrometry)
- Reduces morbidity and mortality from salt-wasting crises
- Particularly benefits males (no genital ambiguity to alert clinicians)
- Death rate without screening: 4-10%
- Screening reduces mean serum sodium at diagnosis (134 mM vs. 124 mM without screening)
Common Pitfalls
Misdiagnosing CSW as SIADH: Always assess volume status clinically; laboratory values alone cannot distinguish these conditions. Treating CSW with fluid restriction (SIADH management) can be fatal 5, 7.
Using potassium citrate instead of potassium chloride in Bartter syndrome: This worsens metabolic alkalosis 1.
Aggressive sodium supplementation in Bartter syndrome with nephrogenic diabetes insipidus: This worsens polyuria and risks hypernatremic dehydration 1.
Overlooking CSW in non-neurosurgical patients: Increasingly recognized in sepsis, status epilepticus, and drug-induced cases 4.
Prenatal NSAID therapy without multidisciplinary oversight: High risk of fetal ductus arteriosus constriction and necrotizing enterocolitis 1.
Confusing systemic vs. renal pseudohypoaldosteronism type 1: Systemic form presents earlier with more severe biochemistry and higher treatment requirements 2.